Gan & Lee Pharmaceuticals(SH 603087, closing price: 59.09 yuan) Released on the evening of February 23announcementAccording to the statement, as of the date of the disclosure of this shareholding reduction plan, Minghua Innovation Technology Investment (Hong Kong) Co., Ltd.Gan & Lee PharmaceuticalsThe company has regarding 80.04 million shares, accounting for 14.25% of the company’s total share capital. Within 6 months following the 15 trading days from the date of this announcement, Minghua Innovation intends to reduce its holdings by a total of regarding 11.23 million shares through centralized bidding transactions, that is, not more than 2% of the company’s total share capital. During the implementation of the relevant shareholding reduction plan, the company distributed dividends, sent bonus shares, increased share capital,Additional issuanceNew crotchorallotmentIn the event of ex-rights or ex-dividend matters, Minghua Innovation can make corresponding adjustments to the shareholding reduction plan according to changes in share capital.
From January to December 2020,Gan & Lee PharmaceuticalsofOperating incomeThe composition is as follows: the pharmaceutical manufacturing industry accounts for 100.0%.
The chairman of Gan Li Pharmaceutical is Gan Zhongru, male, 74 years old, with a doctoral degree; the general manager is Du Kai, male, 45 years old, with a master’s degree.
(Article source: Daily Economic News)
Article source: Daily Economic News
Responsible editor: 91
Original title: Attention!Gan & Lee Pharmaceutical: Shareholder Minghua Innovation plans to reduce its holdings by no more than regarding 11.23 million shares
Solemnly declare: Oriental Fortune.com releases this information for the purpose of disseminating more information and has nothing to do with the position of this site.
